194 related articles for article (PubMed ID: 30406665)
1. Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation.
Liu J; Hanavan PD; Kras K; Ruiz YW; Castle EP; Lake DF; Chen X; O'Brien D; Luo H; Robertson KD; Gu H; Ho TH
J Proteome Res; 2019 Jan; 18(1):331-340. PubMed ID: 30406665
[TBL] [Abstract][Full Text] [Related]
2. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
[TBL] [Abstract][Full Text] [Related]
3. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
[TBL] [Abstract][Full Text] [Related]
4. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
Li L; Miao W; Huang M; Williams P; Wang Y
Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
[TBL] [Abstract][Full Text] [Related]
5. HSP60 silencing promotes Warburg-like phenotypes and switches the mitochondrial function from ATP production to biosynthesis in ccRCC cells.
Teng R; Liu Z; Tang H; Zhang W; Chen Y; Xu R; Chen L; Song J; Liu X; Deng H
Redox Biol; 2019 Jun; 24():101218. PubMed ID: 31112866
[TBL] [Abstract][Full Text] [Related]
6. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
7. PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways.
Feng C; Sun Y; Ding G; Wu Z; Jiang H; Wang L; Ding Q; Wen H
Sci Rep; 2015 Apr; 5():9465. PubMed ID: 25853938
[TBL] [Abstract][Full Text] [Related]
8. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
[TBL] [Abstract][Full Text] [Related]
9. SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer.
Rao H; Liu C; Wang A; Ma C; Xu Y; Ye T; Su W; Zhou P; Gao WQ; Li L; Ding X
Nat Commun; 2023 Nov; 14(1):7572. PubMed ID: 37989747
[TBL] [Abstract][Full Text] [Related]
10. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
[TBL] [Abstract][Full Text] [Related]
11. An actin-WHAMM interaction linking SETD2 and autophagy.
Seervai RNH; Grimm SL; Jangid RK; Tripathi DN; Coarfa C; Walker CL
Biochem Biophys Res Commun; 2021 Jun; 558():202-208. PubMed ID: 33036756
[TBL] [Abstract][Full Text] [Related]
12. Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.
Feng C; Ding G; Jiang H; Ding Q; Wen H
Tumour Biol; 2015 May; 36(5):3457-64. PubMed ID: 25528216
[TBL] [Abstract][Full Text] [Related]
13. SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.
Wang T; Wagner RT; Hlady RA; Pan X; Zhao X; Kim S; Wang L; Lee JH; Luo H; Castle EP; Lake DF; Ho TH; Robertson KD
Mol Oncol; 2024 Jan; 18(1):44-61. PubMed ID: 37418588
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC.
Xue W; Jian W; Meng Y; Wang T; Cai L; Yu Y; Yu Y; Xia Z; Zhang C
Cell Death Dis; 2023 Aug; 14(8):539. PubMed ID: 37604811
[TBL] [Abstract][Full Text] [Related]
15. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
16. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.
Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
[TBL] [Abstract][Full Text] [Related]
17. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
18.
Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
[TBL] [Abstract][Full Text] [Related]
19. Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma.
LaGory EL; Wu C; Taniguchi CM; Ding CC; Chi JT; von Eyben R; Scott DA; Richardson AD; Giaccia AJ
Cell Rep; 2015 Jul; 12(1):116-127. PubMed ID: 26119730
[TBL] [Abstract][Full Text] [Related]
20. Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma.
Yu M; Qian K; Wang G; Xiao Y; Zhu Y; Ju L
Front Oncol; 2023; 13():1114461. PubMed ID: 37025591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
